Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05699525
Other study ID # 21-09023953
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 2024
Est. completion date January 2025

Study information

Verified date April 2024
Source Weill Medical College of Cornell University
Contact Maddy Schier
Phone (646) 289-5271
Email mas4019@med.cornell.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to compare the effectiveness of a standard mobile iPhone cognitive behavioral therapy program to a personalized mobile iPhone cognitive behavioral therapy program that introduces new skills over a shorter period of time. Participants will use the Maya app for two days per week, at least 20 minutes per day, for six weeks. Assessments will include a weekly check in with a member of the research team, questionnaires, and optional magnetic resonance imaging (MRI) and electroencephalographic (EEG) recordings at the beginning and end of the 6-week intervention. The investigators think that that the less burdensome personalized program will be just as effective at improving symptoms of anxiety and depression as the general program.


Description:

Growing evidence suggests a need for anxiety and mood interventions that can be disseminated easily to adolescents and young adults. The goal of this study is to optimize a mobile application that teaches well-established, research-supported psychotherapeutic techniques to adolescents and young adults who are experiencing symptoms of anxiety, depression, and/or bipolar disorder. The study aims to compare the efficacy of a personalized mobile cognitive behavioral therapy program to a more general mobile cognitive behavioral therapy program. Study participants will randomly receive one of two versions of Maya, a mobile cognitive behavior therapy (CBT) app for adolescents and young adults: either a standard version that includes a variety of skills typically used in CBT, or a personalized version with skills matched to the participant's symptom profile. In contrast to the general condition, which may introduce new material over all six weeks of the intervention, all new material in the personalized condition will be introduced within the first four weeks. The remaining two weeks in the personalized condition will consist of practicing previously learned skills. Participants will use the Maya app for two days per week, at least 20 minutes per day for six weeks and will complete assessments at baseline, week 4, week 6 (end of intervention), and a follow-up assessment at week 12. Participants may also choose to complete an optional magnetic resonance imaging (MRI) and/or electroencephalographic (EEG) recording at the baseline and end of intervention (week 6).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date January 2025
Est. primary completion date January 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 25 Years
Eligibility Inclusion Criteria: - Age between 18 and 25 years. - Primary diagnosis of an anxiety, depressive, or bipolar disorder as determined by a score of 4 or greater on the Clinical Severity Rating of the Anxiety Disorders Interview Schedule (ADIS). - If an individual is diagnosed with bipolar disorder, they must be currently euthymic or experiencing a depressive episode. - Access to an Apple iPhone Exclusion Criteria: - History of neurologic disorder that may affect the neural systems of interest or participant's ability to participate - Lifetime diagnosis of a psychotic disorder. - Current hypomanic or manic episode. - Currently in cognitive behavior therapy. - Change in dose of a psychiatric medication in the past 12 weeks. - Initiation of psychotherapy in the past 12 weeks. - Intent or plan to attempt suicide.

Study Design


Intervention

Behavioral:
Personalized MAYA Mobile App
All new material in the personalized condition will be introduced within the first four weeks and will contain modules targeting participant's personal symptom profiles. The remaining two weeks in the personalized condition will consist of practicing previously learned skills.
General MAYA Mobile App
New material will be introduced to participants over all the six weeks of the intervention and will include all application modules.

Locations

Country Name City State
United States Weill Cornell Medical College New York New York

Sponsors (2)

Lead Sponsor Collaborator
Weill Medical College of Cornell University Children's Health Fund

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in anxiety symptoms from pre-intervention to post-intervention as measured by the HAM-A. The primary symptom measure for anxiety will be the Hamilton Rating Scale for Anxiety (HAM-A). The HAM-A is a 14-item questionnaire measure of the severity of anxiety symptoms. The items measure both psychic anxiety and somatic anxiety. The scores range from 0 to 42, where higher scores indicate a greater severity of symptoms and lower scores indicate mild to no anxiety symptoms. Baseline to endpoint [Week 6]
Primary Change in depressive symptoms from pre-intervention to post-intervention as measured by HAM-D. The primary symptom measure for depression will be the Hamilton Rating Scale for Depression (HAM-D). The HAM-D is a 24-item questionnaire measuring the severity of depression symptoms. The scale ranges from 0 to 76, where higher scores indicate higher severity of depressive symptoms. Baseline to endpoint [Week 6]
Primary Change in anxiety symptoms from pre-intervention to post-intervention as measured by the anxiety subscale of the DASS. Anxiety will be measured by the anxiety subscale of the Depression Anxiety Stress Scale (DASS). The anxiety subscale measures of the severity of anxiety symptoms. The scores range from 0 to 42, where higher scores indicate a greater severity of symptoms and lower scores indicate mild to no anxiety symptoms. Baseline to endpoint [Week 6]
Primary Change in depressive symptoms from pre-intervention to post-intervention as measured by the depression subscale of the DASS. Depression will be measured by the depression subscale of the Depression Anxiety Stress Scale (DASS). The subscale measures of the severity of depressive symptoms. The scores range from 0 to 42, where higher scores indicate a greater severity of symptoms and lower scores indicate mild to no symptoms. Baseline to endpoint [Week 6]
Secondary Change in anxiety measure scores pre-intervention to post-active learning phase as measured by HAM-A Anxiety will be measured using the Hamilton Rating Scale for Anxiety (HAM-A). The HAM-A is a 14-item questionnaire measure of the severity of anxiety symptoms. The items measure both psychic anxiety and somatic anxiety. The scores range from 0 to 42, where higher scores indicate a greater severity of symptoms and lower scores indicate mild to no anxiety symptoms. Baseline to end of active learning phase [week 4]
Secondary Change in anxiety measure scores pre-intervention to post-active learning phase as measured by the anxiety subscale of the DASS. Anxiety will be measured by the anxiety subscale of the Depression Anxiety Stress Scale (DASS). The anxiety subscale measures of the severity of anxiety symptoms. The scores range from 0 to 42, where higher scores indicate a greater severity of symptoms and lower scores indicate mild to no anxiety symptoms. Baseline to end of active learning phase [week 4]
Secondary Change in depression measure scores pre-intervention to post-active learning phase as measured by HAM-D. Depression will be scored using the Hamilton Rating Scale for Depression (HAM-D). The HAM-D is a 24-item questionnaire measuring the severity of depression symptoms. The scale ranges from 0 to 76, where higher scores indicate higher severity of depressive symptoms. Baseline to end of active learning phase [week 4]
Secondary Change in depression measure scores pre-intervention to post-active learning phase as measured by the depression subscale of the DASS. Depression will be measured by the depression subscale of the Depression Anxiety Stress Scale (DASS). The subscale measures of the severity of depressive symptoms. The scores range from 0 to 42, where higher scores indicate a greater severity of symptoms and lower scores indicate mild to no symptoms. Baseline to end of active learning phase [week 4]
Secondary Change in social anxiety from pre-intervention to post-intervention as measured by LSAS. Social anxiety will be measured using the Liebowitz Social Anxiety Scale (LSAS). The items measure social anxiety and extent of avoidance. Scores range from 0 to 144 where higher scores indicate higher levels of social anxiety. Baseline to end of active learning phase [week 4 for personalized intervention and week 6 for the general intervention]
Secondary Change in anxiety sensitivity from pre-intervention to post-intervention as measured by ASI. Anxiety sensitivity will be measured using the Anxiety Sensitivity Index (ASI). The items measure distress intolerance and fear of anxiety related sensations. Scores range from 0 to 72 where higher scores indicate higher levels of anxiety sensitivity. Baseline to end of active learning phase [week 4 for personalized intervention and week 6 for the general intervention]
Secondary Change in avoidance from pre-intervention to post-intervention as measured by MEAQ. Experiential avoidance will be measured using the Multidimensional Experiential Avoidance Questionnaire (MEAQ). The 62-item scale measures avoidance of negative internal experiences. Scores range from 62 to 372 where higher scores indicate higher levels of anxiety sensitivity. Baseline to end of active learning phase [week 4 for personalized intervention and week 6 for the general intervention]
Secondary Change in anhedonia from pre-intervention to post-intervention as measured by TEPS. Anhedonia will be measured using the Temporal Experience of Pleasure Scale (TEPS). The items measure anticipatory and consummatory experiences of pleasure. Scores range from 18 to 108 where higher scores indicate stronger feelings of anticipating and experiencing pleasure. Baseline to end of active learning phase [week 4 for personalized intervention and week 6 for the general intervention]
Secondary Change in Negative affect from pre-intervention to post-intervention as measured by PANAS Negative affect will be measured using the negative affect subscale of the Positive and Negative Affect Schedule (PANAS). Scores on the 10-item subscale range from 10 to 50, where higher scores indicate higher levels of negative affect. Baseline to end of active learning phase [week 4 for personalized intervention and week 6 for the general intervention]
Secondary Bipolar symptoms from pre-intervention to post-intervention as measured by ISS. Bipolar symptoms will be measured using the Internal State Scale (ISS). The ISS is a 15 item self-report instrument using a visual analog line scale format (i.e. participant chooses from 0-100 on the scale to respond to each item). The scale contains four subscales (Activation, Well Being, Depression Index, and Perceived Conflict). Scores range from 0 to 1500 where higher scores represent higher severity of symptoms for each subscale. Baseline to end of active learning phase [week 4 for personalized intervention and week 6 for the general intervention]
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A